The kallikrein-kinin system in humans

被引:127
作者
Campbell, DJ
机构
[1] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia
[2] Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia
关键词
bradykinin; kallidin; kallikrein; kallistatin; kininogen;
D O I
10.1046/j.1440-1681.2001.03564.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Kinin peptides are implicated in many physiological and pathological processes, including the regulation of blood pressure and sodium homeostasis, inflammation and the cardioprotective effects of preconditioning. In humans, the plasma and tissue kallikrein-kinin systems (KKS) generate bradykinin and kallidin peptides, respectively. 2. We established methodology for the measurement of bradykinin and kallidin peptides and their metabolites in order to study the function of the plasma and tissue KKS in humans. 3. Bradykinin peptides were more abundant than kallidin peptides in blood and cardiac atrial tissue, whereas kallidin peptides were predominant in urine. The levels of kinin peptides in tissue were higher than in blood, confirming the primary tissue localization of the KKS. 4. Angiotensin-converting enzyme inhibition increased blood levels of bradykinin and kallidin peptides. 5. Blood levels of kallidin peptides were suppressed in patients with severe cardiac failure, indicating that the activity of the tissue KKS is suppressed in this condition. 6. Bradykinin peptide levels were increased in the urine of patients with interstitial cystitis, suggesting a role for these peptides in the pathogenesis and/or symptomatology of this condition. 7. Cardiopulmonary bypass, a model of activation of the contact system, activated both the plasma and tissue KKS. 8. Measurement of individual bradykinin and kallidin peptides and their metabolites gives important information about the operation of the plasma and tissue KKS and their role in physiology and disease states.
引用
收藏
页码:1060 / 1065
页数:6
相关论文
共 35 条
  • [1] An enhanced effect of arginine vasopressin in bradykinin B2 receptor null mutant mice
    Alfie, ME
    Alim, S
    Mehta, D
    Shesely, EG
    Carretero, OA
    [J]. HYPERTENSION, 1999, 33 (06) : 1436 - 1440
  • [2] Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice
    Bergaya, S
    Meneton, P
    Bloch-Faure, M
    Mathieu, E
    Alhenc-Gelas, F
    Lévy, BI
    Boulanger, CM
    [J]. CIRCULATION RESEARCH, 2001, 88 (06) : 593 - 599
  • [3] BHOOLA KD, 1992, PHARMACOL REV, V44, P1
  • [4] Boyle EM, 1997, ANN THORAC SURG, V63, P277
  • [5] Angiotensin-converting enzyme inhibition modifies angiotensin but not kinin peptide levels in human atrial tissue
    Campbell, DJ
    Duncan, AM
    Kladis, A
    [J]. HYPERTENSION, 1999, 34 (02) : 171 - 175
  • [6] Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans
    Campbell, DJ
    Dixon, B
    Kladis, A
    Kemme, M
    Santamaria, JD
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2001, 281 (04) : R1059 - R1070
  • [7] A MAJOR DIFFERENCE OF KALLIKREIN-BINDING PROTEIN IN SPONTANEOUSLY HYPERTENSIVE VERSUS NORMOTENSIVE RATS
    CHAO, J
    CHAO, L
    [J]. JOURNAL OF HYPERTENSION, 1988, 6 (07) : 551 - 557
  • [8] Kallistatin, a novel human tissue kallikrein inhibitor: Levels in body fluids, blood cells, and tissues in health and disease
    Chao, JL
    Schmaier, A
    Chen, LM
    Yang, ZR
    Chao, L
    [J]. JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1996, 127 (06): : 612 - 620
  • [9] Kallistatin is a potent new vasodilator
    Chao, JL
    Stallone, JN
    Liang, YM
    Chen, LM
    Wang, DZ
    Chao, L
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (01) : 11 - 17
  • [10] WILLIAMS TRAIT - HUMAN KININOGEN DEFICIENCY WITH DIMINISHED LEVELS OF PLASMINOGEN PROACTIVATOR AND PREKALLIKREIN ASSOCIATED WITH ABNORMALITIES OF HAGEMAN FACTOR-DEPENDENT PATHWAYS
    COLMAN, RW
    BAGDASARIAN, A
    TALAMO, RC
    SCOTT, CF
    SEAVEY, M
    GUIMARAES, JA
    PIERCE, JV
    KAPLAN, AP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1975, 56 (06) : 1650 - 1662